Newsfeeds - Spark Newswire

3 minute read

Graybug Vision Reports Analysis Of Data From Six-Month Extension Study Of The ALTISSIMO Phase 2b Trial In Wet AMD

Today, 2:46 PM

55% of GB-102 1mg patients in Extension Study experienced duration of 12+ months, while maintaining their visual acuity and central retinal thickness 73% reduction of injection burden for

GRAY

5 minute read

53 Biggest Movers From Friday

By Lisa Levin

Today, 2:46 PM

Gainers Innate Pharma S.A. (NASDAQ: IPHA) shares surged 47.1% to settle at $6.15 on Friday after SVB Leerink upgraded the stock from Market Perform to Outperform.

ADGI

2 minute read

Movers

12 Health Care Stocks Moving In Friday’s Intraday Session

By Benzinga Insights

Today, 2:46 PM

Gainers

APOP

2 minute read

12 Health Care Stocks Moving In Tuesday’s After-Market Session

By Benzinga Insights

Today, 2:46 PM

Gainers

ALT

1 minute read

Graybug Vision Q2 EPS $(0.36) Up From $(6.79) YoY

By Benzinga Newsdesk

Today, 2:46 PM

Graybug Vision (NASDAQ:GRAY) reported quarterly losses of $(0.36) per share. This is a 94.7 percent increase over losses of $(6.79) per share from the same period last year.

GRAY

3 minute read

35 Stocks Moving In Tuesday’s Mid-Day Session

By Lisa Levin

Today, 2:46 PM

Gainers

ALF

2 minute read

22 Stocks Moving in Tuesday’s Pre-Market Session

By Lisa Levin

Today, 2:46 PM

Gainers Exela Technologies, Inc. (NASDAQ: XELA) rose 39% to $2.05 in pre-market trading after gaining over 5% on Monday.

ALGS

5 minute read

61 Biggest Movers From Yesterday

By Lisa Levin

Today, 2:46 PM

Gainers Marin Software Incorporated (NASDAQ: MRIN) surged 96.9% to close at $7.50. Marin Software, last week, announced it has added the ability to manage Instacart Ads to its flagship MarinOne platform.

ACXP

2 minute read

Movers

12 Health Care Stocks Moving In Monday’s Intraday Session

By Benzinga Insights

Today, 2:46 PM

Gainers

APLT

4 minute read

44 Stocks Moving In Monday’s Mid-Day Session

By Lisa Levin

Today, 2:46 PM

Gainers Intellia Therapeutics, Inc. (NASDAQ: NTLA) shares climbed 43.5% to $127.44 after the company announced positive clinical data for its CRISPR therapy.

ACXP